GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.58 USD | -0.52% |
|
-1.15% | -20.28% |
| May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
| May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 27.6B | Sales 2025 * | 28B | Capitalization | 80.95B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.59 x |
| Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.34 x |
| P/E ratio 2024 * |
184
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
| Yield 2024 * |
4.77% | Yield 2025 * |
5.01% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | -0.52% | ||
| 1 week | -1.15% | ||
| Current month | -0.95% | ||
| 1 month | -7.66% | ||
| 3 months | -12.34% | ||
| 6 months | -13.87% | ||
| Current year | -20.28% |
1 week
64.33
66.14
1 month
64.3369.76
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 0 M€ | +11.39% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 64.92 | -0.82% | 5,134,980 |
| 24-05-07 | 65.46 | -0.12% | 7,318,161 |
| 24-05-06 | 65.54 | +1.17% | 7,187,265 |
| 24-05-03 | 64.78 | -0.84% | 7,822,720 |
| 24-05-02 | 65.33 | -0.27% | 5,571,500 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.92
USD
Average target price
82.93
USD
Spread / Average Target
+27.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 80.95B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- GILD Stock